# (19) World Intellectual Property Organization International Bureau





## (43) International Publication Date 14 February 2002 (14.02.2002)

**PCT** 

# (10) International Publication Number WO 02/011756 A3

- (51) International Patent Classification?: A61K 39/00, C07K 14/445, C12N 15/12, 15/63, C07K 16/20, A61P 33/02
- (21) International Application Number: PCT/US01/24725
- (22) International Filing Date: 7 August 2001 (07.08.2001)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/223,525

7 August 2000 (07.08.2000) US

- (71) Applicant (for all designated States except US): EN-TREMED, INC. [US/US]; 9640 Medical Center Drive, Suite 200, Rockville, MD 20850 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): NARUM, David, L. [US/US]; 8533 Fountain Valley Drive, Gaithersburg, MD 20879 (US). SIM, Kim, L. [US/US]; 308 Argosy Drive, Gaithersburg, MD 20878 (US).
- (74) Agents: SHOPE, Suzanne, S. et al.; Kilpatrick Stockton LLP, Suite 2800, 1100 Peachtree Street, Atlanta, GA 30309 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


#### Published:

with international search report

(88) Date of publication of the international search report: 9 January 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTI-PLASMODIUM COMPOSITIONS AND METHODS OF USE



P. vivax/P. knowlesi
Duffy-binding proteins

P. falciparum EBA-175

(57) Abstract: Compositions that inhibit the binding of Plasmodium falciparum to erythrocytes include a family of erythrocyte binding proteins (EBPs). The EBPs are paralogues of the P. falciparum binding protein EBA-175. The present invention includes peptides of the paralogues that prevent the binding of P. falciparum. Antibodies specific for each paralogue that also prevent the binding of P. falciparum are also included. Methods of the invention utilize the paralogues, antibodies thereof and peptide compositions for the diagnosis, prevention, and treatment of P. falciparum diseases such as malaria, as well as methods for the detection of P. falciparum in biological samples and culture media.

/O 02/011756 A3

### INTERNATIONAL SEARCH REPORT

li ional Application No

A. CLASSI IPC 7	FICATION OF SUBJECT MATTER A61K39/00 C07K14/445 C12N15/1 A61P33/02	2 C12N15/63 C07	K16/20			
According to	According to International Patent Classification (IPC) or to both national classification and IPC					
	SEARCHED					
Minimum documentation searched (classification system followed by classification symbols)  IPC 7 C12N C07K A61K						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
Electronic d	ata base consulted during the international search (name of data bas	se and, where practical, search terms us	sed)			
EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE, EMBL						
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with Indication, where appropriate, of the rele	evant passages	Relevant to claim No.			
X	PETERSON DAVID S ET AL: "Isolati multiple sequences from the Plasm falciparum genome that encode condomains homologous to those in erythocyte-binding proteins." PROCEEDINGS OF THE NATIONAL ACADE SCIENCES OF THE UNITED STATES, vol. 92, no. 15, 1995, pages 7100 XP002207620 1995 ISSN: 0027-8424	nodium iserved EMY OF	1,3,4,6, 8,10,12, 13,16-20			
Further documents are listed in the continuation of box C.  Patent family members are listed in annex.						
° Special ca	tegories of cited documents:	IT? Inter decument published after the	international filing data			
*A* document defining the general state of the art which is not		"T" later document published after the lor priority date and not in conflict we clied to understand the principle or	ith the application but			
consid	lered to be of particular relevance document but published on or after the international	Invention				
filing date cannot be considered novel or cannot be consi			not be considered to			
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the			e claimed invention			
*O* document referring to an oral disclosure, use, exhibition or other means one other such document is combined with one or more other			more other such docu-			
*P* document published prior to the international filing date but		in the art.  &' document member of the same patent family				
Date of the actual completion of the international search		Date of mailing of the International				
26 July 2002		07/08/2002				
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentiaan 2		Authorized officer	•			
NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo ni, Fax: (+31–70) 340–3016		Mata Vicente, T.				

### INTERNATIONAL SEARCH REPORT

ational Application No

		101/US 01/24725
C.(Continua	ition) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KAPPE STEFAN H I ET AL: "Erythrocyte binding protein homologues of rodent malaria parasites." MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 89, no. 1, 1997, pages 137-148, XP002207621 ISSN: 0166-6851 page 138	1,3,4,6, 8,10,12, 13,16-20
X	DATABASE EMBL 'Online! EBI; 15 March 1999 (1999-03-15) "Plasmodium falciparum genome sequence" Database accession no. AL049180 XP002207624	6-12
P,X	MAYER D C GHISLAINE ET AL: "Characterization of a Plasmodium falciparum erythrocyte-binding protein paralogous to EBA-175." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 9, 24 April 2001 (2001-04-24), pages 5222-5227, XP002207622 April 24, 2001 ISSN: 0027-8424 the whole document	1-20
P,X	TRIGLIA TONY ET AL: "An EBA175 homologue which is transcribed but not translated in erythrocytic stages of Plasmodium falciparum."  MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 116, no. 1, August 2001 (2001-08), pages 55-63, XP002207623 ISSN: 0166-6851 abstract	1,3,4,6, 8,10,12, 13,16-20
·		

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

ernational application No.
PCT/US 01/24725

### INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)			
This international Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:			
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:			
Although claims 13-15 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.			
2. X Claims Nos.:  because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:			
see FURTHER INFORMATION sheet PCT/ISA/210			
3. Ctaims Nos.:			
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box II Observations where unity of Invention is lacking (Continuation of Item 2 of first sheet)			
This International Searching Authority found multiple inventions in this international application, as follows:			
1. As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.			
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.			
3. As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:			
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:			
Remark on Protest The additional search fees were accompanied by the applicant's protest.			
No protest accompanied the payment of additional search fees.			

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

The applicant's attention is drawn to the fact that the sequence identified as SEQ ID NO:1 filed with the application is not a nucleotidic sequence but a polypeptide. Moreover, no polynucleotide sequence has been filed and, thereof, the sequence search has been carried out based on SEQ ID NO:1 (and assuming that that is the protein subject of the invention) and on its T-DNA sequence.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.